Sweden Restricts Puberty Blockers to Research Settings Nationally
Sweden's National Board of Health and Welfare published national guidelines concluding that the risks of puberty blockers and gender-affirming hormonal treatment for under-18s were likely to outweigh the expected benefits. Hormonal treatments were restricted to ethically approved research settings only, following Karolinska Hospital's earlier policy shift and citing evidence reviews from both Sweden and the UK.
Impact & Significance
Sweden became the first country to formally restrict puberty blockers nationally to research-only settings, providing a model that Norway and other Nordic countries would subsequently follow.
Reference Record
- Date
- 22 February 2022
- Era
- 2020-present
- Sources
- 2
This timeline entry is being migrated into the reference platform. Source metadata and editorial review status will be strengthened as each topic is upgraded.
